Only USPSTF grades A and B must be covered by most insurance plans at no cost. What that means for PSA tests and calcium scans, and why both are stuck.
Cancer risk by age, for men, with smoking, weight and alcohol toggles: out of 10,000 U.S. men aged 50, about 145 die of cancer within ten years. Prostate tops the list of cancers men get at 50, 60, 70 and 80, and reaches the top two of the list that kills only at 70 and 80.
The deadliest cancers for men over 50, by age band; what half a century of progress actually bought; and the one screening decision where three expert bodies still disagree. By Gunnar · Not medical advice · Every number links to its source · September 15, 2026 · Editorial standards Among cancers, lung cancer is the
A hacked small-town government website is ranking on Google for real peptide brands and redirecting searchers into a WhatsApp sales operation.
Updated September 17, 2026 with a plain answer up top on what is and isn’t known. Brenipatide side effects: thirteen registered trials, ten conditions, and not one has reported. Here is what is actually known. I take tirzepatide every Friday, so I know exactly what a GLP-1 does to a digestive system. Brenipatide works on
My calcium score is zero and my ApoB was flagged high. When the 2026 guideline lets a zero defer a statin, the four exceptions, how long a zero lasts, and what I did.
I read the study behind the alcohol and cancer deaths headlines. Since 1990, the national rate rose modestly — men 55 and older saw by far the sharpest increase.
Both machines live in my garage. With a bone-on-bone knee, the bike gets most of the work, and the knee-loading studies support that order.
Pelacarsen missed its primary endpoint in the Lp(a)HORIZON trial. Here’s what’s actually known, what two doctors think happened, and why I’m putting my own effort back into LDL and ApoB instead of waiting on an Lp(a) drug.
I paid Lilly’s self-pay price for Zepbound for months, and retatrutide has no announced price yet, so here is what Lilly’s own price ladders imply.
